BridgeMD
A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors
EU CTIS ID: 2024-512135-80-00
What this study is testing
To determine the Objective Response Rate (ORR) at Week 16, by each tumor type, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) (for High Grade Glioma [HGG] only) as assessed by the investigator.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Has histologically or cytologically documented relapsed, or refractory pediatric solid malignancy excluding osteosarcoma
- 10. Male participants must agree to use approved contraception during the treatment period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period
- 2. Has measurable disease as defined by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for High Grade Glioma (HGG)
- 3. Has a performance status defined as follows: 1) Lansky Play Score ≥50 for participants up to and including 16 years of age 2) Karnofsky performance status (KPS) ≥50 for participants >16 years of age 3) Neurologic deficits in participants with primary central nervous system (CNS) tumors must have been stable for at least 7 days prior to study enrollment
- 4. Demonstrate adequate organ function
- 5. No clinical evidence of nephrotic syndrome.
You likely can't join if
- 1. Has had major surgery within 3 weeks prior to Cycle 1 Day 1 (C1D1)
- 10. Known to be Human immunodeficiency virus (HIV) positive
- 11. Known active viral hepatitis (B or C) as demonstrated by positive serology. Testing for hepatitis B or hepatitis C is required at screening only when mandated by local health authority
- 12. Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation
- 13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- 14. Has known hypersensitivity to any component of the investigational product (lenvatinib or ingredients)
See the full eligibility criteria
Who can join
- 1. Has histologically or cytologically documented relapsed, or refractory pediatric solid malignancy excluding osteosarcoma
- 10. Male participants must agree to use approved contraception during the treatment period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period
- 2. Has measurable disease as defined by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for High Grade Glioma (HGG)
- 3. Has a performance status defined as follows: 1) Lansky Play Score ≥50 for participants up to and including 16 years of age 2) Karnofsky performance status (KPS) ≥50 for participants >16 years of age 3) Neurologic deficits in participants with primary central nervous system (CNS) tumors must have been stable for at least 7 days prior to study enrollment
- 4. Demonstrate adequate organ function
- 5. No clinical evidence of nephrotic syndrome.
- 6. Has adequate blood pressure (BP) control with or without antihypertensive medications
- 7. Has adequate cardiac function
- 8. Has adequate neurologic function
- 9. Participant must have fully recovered to Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) Grade ≤1 (except for alopecia, ototoxicity, and Grade ≤2 peripheral neuropathy) from the acute toxic effects of all prior anticancer therapy
What rules you out
- 1. Has had major surgery within 3 weeks prior to Cycle 1 Day 1 (C1D1)
- 10. Known to be Human immunodeficiency virus (HIV) positive
- 11. Known active viral hepatitis (B or C) as demonstrated by positive serology. Testing for hepatitis B or hepatitis C is required at screening only when mandated by local health authority
- 12. Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation
- 13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- 14. Has known hypersensitivity to any component of the investigational product (lenvatinib or ingredients)
- 15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the stud
- 16. Has clinically significant cardiovascular disease within 6 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
- 17. Has non-healing wound, tumor ulceration, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment
- 2. Has gastrointestinal (GI) bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrollment
- 3. Has CNS tumors with a history of symptomatic tumor hemorrhage
- 4. Has evidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment
- 5. Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation
- 6. Has evidence of untreated CNS metastases (exception: participants with primary CNS tumors and leptomeningeal disease.
- 7. Has GI malabsorption, GI anastomosis, or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib
- 8. Has preexisting ≥Grade 3 GI or non-GI fistula
- 9. Has any active infection requiring systemic therapy
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- New Zealand
- Israel
- Peru
- Turkey
- Korea, Republic of
- Argentina
- Serbia
- Guatemala
- Russian Federation
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; New Zealand; Israel; Peru; Turkey; Korea, Republic of and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.